Galderma wins China NMPA approval for Relfydess wrinkle treatment
China's NMPA has approved Relfydess for frown lines in adults. The decision rests on Phase III data from a local trial conducted in China, Reuters reported.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Swiss company Galderma Group said China's regulator NMPA has approved Relfydess for treating frown lines in adults. According to Reuters, the decision is based on Phase III results from a local clinical trial run in China, together with global clinical trials.
The company said the local results reinforce that Relfydess delivers significant improvements in frown lines.
why it matters
The approval extends Galderma's reach into China's large aesthetic medicine market. For the broader market the news is mostly local, and the text gives no sign of a wider effect on shares or the sector.
tags
instruments
sources
- Galderma Receives Chinese Nmpa Approval For Relfydess For Frown Lines In Adults — Reuters, 23 October 2026 at 05:03 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗